Gary Friedman

Prof. Gary Friedman

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2024 in Advanced Functional Materials
Verified
Journal Article
Closed access
RRRoman Rakhmanov
Roman Rakhmanov
SIStefano Ippolito
Stefano Ippolito
MDMarley Downes
Marley Downes
AIAlex Inman
Alex Inman
JAJamal AlHourani
Jamal AlHourani
GFGary Friedman
Gary Friedman

1 April 2004 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
PDF file
AMA Scott Mathis
A Scott Mathis
NDNisha Davé
Nisha Davé
NSNita K Shah
Nita K Shah
GFGary Friedman
Gary Friedman
BACKGROUND Heparin can reduce the risk of renal artery/vein thrombosis in renal transplant patients with hypercoagulable states (HCS), but is associated with a high bleeding risk. Little is known about risk factors for this bleeding risk or the optimal anticoagulation target. OBJECTIVE To determine factors associated with this bleeding risk and determine the optimal partial thromboplastin time (PTT) ratio. METHODS We retrospectively reviewed medical records of consecutive adult renal transplant recipients administered heparin for perioperative renal thrombosis prevention (1998–2002). RESULTS Twenty-eight (3.86%) of 725 consecutive renal transplant recipients received heparin to prevent renal thrombosis. Eighteen patients (64.3%) had clinically important bleeding (14 major bleeding). Patients with and without bleeding were similar in baseline demographic characteristics and overall mean PTT. Bleeding occurred at a mean PTT ratio of 2.5 ± 1, higher than the overall mean in bleeders and nonbleeders (p = 0.001). Among postoperative characteristics, higher maximum PTT (p = 0.052) and prolonged surgical antibiotic prophylaxis (p = 0.053), particularly with cefotetan (p = 0.091), trended toward a significant association with bleeding. Two renal thrombotic episodes occurred, both at PTT ratios <1.5. A PTT ratio of 1.5–1.9 resulted in no thrombosis and ≤4.2% bleeding. CONCLUSIONS The benefits and risks of therapeutic heparin anticoagulation in renal transplant patients with HCSs were confirmed. Higher PTTs and cefotetan antibiotic surgical prophylaxis could contribute to bleeding. The optimal PTT ratio appeared to be 1.5–1.9 to prevent thrombosis and limit bleeding risk.

13 November 2023 in Applied Physics Letters
Verified
Journal Article
Open access
PDF file
RRRoman Rakhmanov
Roman Rakhmanov
CSChristopher Eugene Shuck
Christopher Eugene Shuck
JHJamal Al Hourani
Jamal Al Hourani
SIStefano Ippolito
Stefano Ippolito
Yury GogotsiYury Gogotsi
Yury Gogotsi
GFGary Friedman
Gary Friedman
The quick progress in communication technologies demands superior electromagnetic interference (EMI) shielding materials. However, achieving a high shielding effectiveness (SE) with thin films, which is needed for microscale, flexible, and wearable devices, through absorption of EM radiation remains a challenge. 2D titanium carbide MXene, Ti3C2Tx, has been shown to efficiently reflect electromagnetic waves. In this paper, we investigated the electromagnetic shielding of ultrathin printed Ti3C2Tx films and recorded absorption up to 50% for 4 nm-thick films. This behavior is explained by impedance matching. Analysis of the sheet impedance in the X-band frequency range allows us to correlate the EMI shielding mechanism with the electrical conductivity measured within the same range. The average bulk in-plane conductivity for 4 to 40 nm-thick films reaches 106 S/m, while the average relaxation time is estimated at around 2.3 ps. Our figures of merit are similar to those reported for ultrathin metal films, such as gold, showing that an abundant MXene material can replace noble metals. We demonstrate that the MXene conductivity mechanism does not change from direct current to THz. The conventional method of reporting EMI SE is correlated with absolute values of transmitted, reflected, and absorbed power, which allows us to interpret previous results on MXene EMI shielding. Considering the easy deposition of thin MXenes films from solution onto a variety of surfaces, our findings offer an attractive alternative for shielding microscale devices and personal electronics.

16 July 2021
Verified
Thesis
Closed access
HAHalim Ayan
Halim Ayan
GFGary Friedman
Gary Friedman
AFAlexander A. Fridman
Alexander A. Fridman
For some period of time the use of plasma in medicine has been limited to thermal discharges for cauterization and dissection. The effects of thermal plasma on tissue are entirely related to local heating. Non-thermal plasma, on the other hand, can have many different modes of interaction with tissue. It has been recently demonstrated that direct treatment of smooth surfaces by non-thermal dielectric barrier discharge (DBD) in air is highly effective in killing pathogens. Moreover, DBD can create different sub-lethal and selective effects. These results hold significant promise for medical applications such as sterilization of wound surfaces. However, a typical DBD in air can be highly non-uniform, particularly on topographically non-uniform surfaces such as in most living tissues. This creates significant limitations for use of DBDs in wound care and other biomedical applications. In this thesis, a novel non-thermal plasma system, namely nanosecondpulsed DBD, has been developed and investigated to address this important limitation. Nanosecond-pulsed DBD is shown to be uniform in air at atmosphericpressure and much more effective in killing bacteria than conventional DBDs, particularly on topographically non-uniform surfaces. Thus, this new plasma system is potentially convenient for in vivo and hospital sterilization cases.

16 July 2021
Verified
Thesis
Closed access
GFGregory Fridman
Gregory Fridman
GFGary Friedman
Gary Friedman
For some time, plasma has been used in medicine to cauterize or cut tissue using heat and mechanical energy. In the recent decade, some researchers around the world have started to investigate how gas jets that pass through thermal plasma can be employed in medicine. This thesis presents the first investigation of biomedical uses of non-thermal plasma discharge which comes in direct contact with living tissue. It is demonstrated that the direct application of non-thermal plasma in air can cause rapid deactivation of bacteria on surfaces of tissues without causing any visible tissue damage. Medical need for such a device is discussed. Construction and operation of various types of non-thermal plasma power supplies and many types of treatment electrodes are presented as well. Application of this plasma to living organisms is shown to be safe from both the electrical perspective and from the biologicalperspective. Biological safety is revealed through a series of differential skin toxicity trials on human cadaver tissue, live hairless mouse skin tissue, live pig skin tissue, and finally in an open wound model on pigs. Direct non-thermal plasma in air is shown to deactivate bacteria about 100 times faster than indirect application using jets. A series of experiments reveal that this effectiveness is due to the ability of direct discharge to bring charges to tissue surfaces. It is demonstrated that neither ultraviolet (UV) radiation nor neutral active species such as hydroxyl radicals or ozone produced in plasma are responsible for the main effect on bacteria. Although much additional work remains on establishing detailed mechanism by which chargesfrom plasma achieve this effect, the work carried out in this thesis clearly demonstrates that direct application of non-thermal plasma in air can be a very useful tool in medicine.